Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs

Epidermal growth factor receptors 1 and 2 (EGFR and HER2) are frequently overexpressed in various malignancies. Lapatinib is a dual tyrosine kinase inhibitor that inhibits both EGFR and HER2. Although a phase III trial failed to show the survival benefits of lapatinib treatment after first-line chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeda, Shingo, Sakai, Kosei, Kaji, Kenjiro, Iio, Aki, Nakazawa, Maho, Motegi, Tomoki, Yonezawa, Tomohiro, Momoi, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758709/
https://www.ncbi.nlm.nih.gov/pubmed/35027594
http://dx.doi.org/10.1038/s41598-021-04229-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758709/
https://www.ncbi.nlm.nih.gov/pubmed/35027594
http://dx.doi.org/10.1038/s41598-021-04229-0

Ejemplares similares